Opportunities to widen your network and absorb deep business and legal insight.

The Future of Life Science: Speaking With the Game Changers in Genomics

07 June 2018


  • Foley & Lardner LLP
    111 Huntington Avenue
    Suite 2500
    Boston, MA 02199


6:00 p.m. - 6:30 p.m. Registration
6:30 p.m. - 8:00 p.m. Panel Discussion
8:00 p.m. - 9:00 p.m. Networking/Cocktails

Contact Information

Allison Jones

Foley is pleased to host a “think tank” panel discussion featuring genomics and cell therapy leaders from academia, business, and consumer entities on Thursday, June 7, 2018, after the BIO International Convention, presented in partnership with IMPACTIV BioConsult and Ellipsis LLC.

This program is intended for C-level executives from biotechnology, genomics, and pharmaceutical companies as well as investors looking for ways to evaluate future trends in the industry.

A revolutionary storm is brewing within the life sciences industry — from both a scientific and a business perspective, genomics is expected to play a key role in driving change to the point where we may not even recognize the industry 5-10 years from now. But how will genomics evolve, who are likely to be the key players in driving the change, and how can we look at what is happening today as an indication of how the future might unfold?

While it is evident that widespread innovation is taking place throughout the community by everyone from high-profile academia and life science-focused businesses to companies involved in consumer-facing applications, what we do not yet know is how this broad spectrum of players will contribute to change both as individual entities and as potential collaborators, and what the effects will be on funding, R&D, regulatory pathways and approval, and other corporate activities.

Join us after the 2018 BIO International Convention for this “think tank” panel discussion featuring genomics and cell therapy leaders from academia, business, and consumer entities. Together, we will dissect the future of the industry and contemplate what may be the near- and long-term future of genomics.


Andrea Bartzen, Founder, IMPACTIV BioConsult


David Berry, MD, PhD, Partner, Flagship Ventures
John Sullivan, CFA, Senior Managing Director, Equity Research & Healthcare Investment Strategist, Leerink Partners
Benoit Destenaves, PharmD, Director – Precision Medicine Lead, AstraZeneca
Szilard Voros, MD, Founder & CEO, Global Genomics Group (G3)
Ohad Karnieli, PhD, Chief Executive Officer & Co-Founder, ATVIO Biotechnology
Bill Farley, Vice President of Sales and Business Development, Sorrento Therapeutics
Akwasi Asabere, PhD, Business Development & Partnerships, Helix

There is no fee to attend this program, but advance registration is required. Click here to register.